The Prognostic Value of Serum Biomarkers for Survival of Children with Osteosarcoma of the Extremities.
C-reactive protein
alkaline phosphatase
chemotherapy-induced tumor necrosis
children
erythrocyte sedimentation rate
local recurrence
osteosarcoma
prognosis
serological biomarker
survival
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
24 07 2023
24 07 2023
Historique:
received:
28
04
2023
revised:
28
06
2023
accepted:
21
07
2023
medline:
31
7
2023
pubmed:
28
7
2023
entrez:
28
7
2023
Statut:
epublish
Résumé
Osteosarcoma is a highly aggressive malignant bone tumor that affects mainly adolescents and young adults. We analyzed serum biomarkers for their prognostic significance in children with osteosarcoma. In this retrospective study, we investigated the prognostic factors in 210 children who were treated for appendicular osteosarcoma, including patient age and sex, tumor site and size (≥8 cm or <8 cm), presence of metastasis, chemotherapy-induced tumor necrosis, serum levels of alkaline phosphatase (AP), C-reactive protein, serum hemoglobin, lactate dehydrogenase, erythrocyte sedimentation rate (ESR), leukocyte counts, platelet count, and neutrophil-lymphocyte ratio. A multivariate Cox regression model showed that high level of AP [HR of 1.73; 95% CI, 1.02 to 2.94], poor chemotherapy-induced tumor necrosis [HR of 2.40; 95% CI, 1.41 to 4.08] and presence of metastases at presentation [HR of 3.71; 95% CI, 2.19 to 6.29] were associated with poor prognosis at 5 years ( AP and ESR can identify osteosarcoma-diagnosed children with a greater risk of death and local recurrence, respectively.
Sections du résumé
BACKGROUND
Osteosarcoma is a highly aggressive malignant bone tumor that affects mainly adolescents and young adults. We analyzed serum biomarkers for their prognostic significance in children with osteosarcoma.
METHODS
In this retrospective study, we investigated the prognostic factors in 210 children who were treated for appendicular osteosarcoma, including patient age and sex, tumor site and size (≥8 cm or <8 cm), presence of metastasis, chemotherapy-induced tumor necrosis, serum levels of alkaline phosphatase (AP), C-reactive protein, serum hemoglobin, lactate dehydrogenase, erythrocyte sedimentation rate (ESR), leukocyte counts, platelet count, and neutrophil-lymphocyte ratio.
RESULTS
A multivariate Cox regression model showed that high level of AP [HR of 1.73; 95% CI, 1.02 to 2.94], poor chemotherapy-induced tumor necrosis [HR of 2.40; 95% CI, 1.41 to 4.08] and presence of metastases at presentation [HR of 3.71; 95% CI, 2.19 to 6.29] were associated with poor prognosis at 5 years (
CONCLUSIONS
AP and ESR can identify osteosarcoma-diagnosed children with a greater risk of death and local recurrence, respectively.
Identifiants
pubmed: 37504371
pii: curroncol30070511
doi: 10.3390/curroncol30070511
pmc: PMC10378558
doi:
Substances chimiques
Biomarkers
0
Antineoplastic Agents
0
Banques de données
ClinicalTrials.gov
['NCT05093101']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7043-7054Références
Cancer Treat Rev. 2006 Oct;32(6):423-36
pubmed: 16860938
Transl Oncol. 2017 Dec;10(6):942-948
pubmed: 29031130
World J Surg Oncol. 2016 Apr 29;14:127
pubmed: 27125872
Bone Joint J. 2013 Mar;95-B(3):411-8
pubmed: 23450030
Cancer Med. 2017 Jun;6(6):1311-1322
pubmed: 28493412
J Surg Oncol. 2003 Nov;84(3):151-9
pubmed: 14598359
Jt Dis Relat Surg. 2021;32(2):489-496
pubmed: 34145828
Front Oncol. 2016 Feb 02;6:22
pubmed: 26904501
Mediators Inflamm. 2021 Oct 21;2021:3456629
pubmed: 34720749
Cancer Treat Rev. 2013 Aug;39(5):534-40
pubmed: 22995477
J Pediatr Hematol Oncol. 2017 Oct;39(7):538-546
pubmed: 28697168
Tumour Biol. 2015 Sep;36(10):7515-20
pubmed: 25913621
BMC Cancer. 2022 Dec 30;22(1):1370
pubmed: 36585638
J Orthop Surg (Hong Kong). 2019 May-Aug;27(2):2309499019838293
pubmed: 30909848
Oncol Rep. 2002 Jan-Feb;9(1):171-5
pubmed: 11748477
Tumour Biol. 2015 Jul;36(7):5663-6
pubmed: 25986475
Cancer. 2009 Apr 1;115(7):1531-43
pubmed: 19197972
Transl Oncol. 2016 Aug;9(4):322-8
pubmed: 27567955
Eur J Cancer Care (Engl). 2017 Sep;26(5):
pubmed: 27349943
J Surg Oncol. 2013 Dec;108(7):481-5
pubmed: 24018883
Cancer. 2012 Feb 15;118(4):1055-61
pubmed: 21761398
Cancer. 2006 Mar 1;106(5):1154-61
pubmed: 16421923
Dis Markers. 2020 Jan 07;2020:8736509
pubmed: 31998420
Clin Oncol (R Coll Radiol). 2019 Apr;31(4):242-249
pubmed: 30744933
Int J Gen Med. 2021 Aug 26;14:4819-4827
pubmed: 34475776
Indian J Orthop. 2014 May;48(3):247-54
pubmed: 24932029
Cells. 2021 Jan 15;10(1):
pubmed: 33467756
Am J Surg. 2001 Aug;182(2):197-201
pubmed: 11574097
Nutr Cancer. 2004;48(2):171-3
pubmed: 15231451
Onco Targets Ther. 2017 Nov 02;10:5255-5261
pubmed: 29138578
Rheumatol Ther. 2016 Dec;3(2):221-243
pubmed: 27761754
Tumori. 1999 Nov-Dec;85(6):458-64
pubmed: 10774566